Preparation for generic competition
Pharmacloud was approached by a major global pharmaceuticals company to help it prepare for loss of market exclusivity of the biggest product in one of its key therapeutic franchises. Specifically, Pharmacloud was asked to assess the likely tactics that generic entrants to the market would use to gain market share and to advise the client on how best to respond to these. Pharmacloud also worked with the local European country managers to understand their plans for defending the sales of the product and to suggest ways in which these could be improved, given the expected behaviour of the competition and the local regulatory environment (e.g. mandatory price cuts or the introduction of co-pays once generics were approved).
To fulfil this assignment, Pharmacloud used its own knowledge and industry contacts to gain a thorough understanding of the current and likely future competitive landscape within the therapeutic area in question. We combined this with insights from the client’s country managers, in order to come up with likely scenarios for each market, together with practical suggestions for mitigating the impact of generics and maximising overall revenue for the legacy product.
Biosimilar market modelling
Pharmacloud was asked by a leading global generics company to help it in assessing the viability of two of its biosimilar development candidates. Pharmacloud’s task was to model out the expected development of the market for these two products in the US, taking into consideration both the expected outlook for the originator product (including the possibility that it would be superseded by superior therapies before the launch of any biosimilars) and the likely evolution of the US biosimilar market as a whole.
As part of this project, Pharmacloud mapped out the therapeutic spaces in which these two molecules sit and produced models for the likely future sales of the originator products. We then considered two different scenarios for the US biosimilar market, one in which interchangeability was possible and one in which it was not, and calculated likely market shares, sales prices and ROIs for the client’s products under both scenarios. This work was then fed into the client’s overall evaluation of its pre-clinical pipeline, enabling it to best allocate its R&D resources.< Back